COVAX Publishes First Interim COVID-19 Vaccine Distribution Forecast

The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines, published COVAX’s first interim COVID-19 vaccine distribution forecast. 

Building on the 2021 COVAX global and regional supply forecast publication, the interim distribution forecast provides information on the early projected availability of doses of the Pfizer/BioNTech vaccine in Q1 2021 and the AstraZeneca/Oxford vaccine candidate in the first half of 2021 to the COVAX Facility participants. 

On February 3, 2021, this announcement comes less than two weeks after the announcement of the signed advance purchase agreement with Pfizer/BioNTech and a little more than a month after the first COVID-19 vaccine received WHO Emergency Use Listing (EUL) approval.

The purpose of sharing the interim distribution with countries, even in today’s highly dynamic global supply environment, is to provide governments and health systems with the information they need to plan for their national vaccination programs. 

‘Final allocations will be published in due course,’ stated the announcement.

The interim distribution forecast outlines projected delivery of vaccine doses to all Facility participants, except for participants who have either exercised their rights to opt-out, have not submitted vaccine requests, or have not yet been allocated doses.

This document contains information on the indicative distribution of 240 million doses of the AstraZeneca/Oxford vaccine, licensed to Serum Institute of India (SII) – in the future “AZ/SII.”

And 96 million doses of the AstraZeneca/Oxford vaccine, under the advance purchase agreement between Gavi, the Vaccine Alliance, and AstraZeneca – hereinafter “AZ,” for Q1 & Q2 2021. 

The interim analysis also contains an overview of the impressive first-round allocation of 1.2 million doses of the WHO EUL-approved Pfizer-BioNTech vaccine – from now on “Pfizer-BioNTech,” for Q1 2021. 

It is important to note additional doses of both these vaccine products will be available to the COVAX Facility in 2021.

The full report can be found at this link.  

PrecisionVaccinations publishes research-based vaccine news.